With its latest $50 billion U.S. manufacturing investment and record U.S. growth, is British AstraZeneca looking at itself as ...

In addition, the company recently announced $50 billion in manufacturing commitments in the US — including a brand-new facility in Virginia — and stated its goal of having 50% of its revenue come from ...

Cancer drug demand drives higher sales for AstraZeneca - Revenues from oncology products made up 43% of the company’s total ...

The Anglo-Swedish pharmaceutical giant said Tuesday that for the second quarter, core earnings per share rose to $2.17 from $1.98 in the same period a year prior. Revenue increased to $14.46 billion ...

(Alliance News) - AstraZeneca PLC on Tuesday reported better-than-expected second quarter revenue, and raised its dividend, boosted by strong sales from its cancer portfolio.

(Alliance News) - AstraZeneca raised its dividend as drug growth pushed earnings higher, Barclays launched a new buyback programme after profit jumped while Greggs saw profit fall despite higher sales ...

AstraZeneca PLC (NASDAQ: AZN) ranks among the stocks to benefit from an onshoring boom. AstraZeneca PLC (NASDAQ:AZN) ...

AstraZeneca has announced a sweeping $50 billion investment across the United States through 2030, marking the company’s largest commitment to U.S. pharmaceutical operations to date. The move signals ...

Democrats assert in the court case that the vote of a Senate committee rejecting the appointees means they cannot serve. A ...

The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

The Trump trade deals should be major boosts to the American economy, and more deals are on the way. It was a special opportunity and I was honored to be present for the finalization of such an ...

AstraZeneca's shares are up 3.5% over the year to date but remain down 11% over the past 52 weeks.